Briacell Therap (NASDAQ:BCTX) Shares Up 1.1% – What’s Next?

Briacell Therap (NASDAQ:BCTX) shares shot up 1.1% during mid-day trading on Tuesday . The company traded as high as $3.65 and last traded at $3.63. Approximately 109,117 shares traded hands during mid-day trading, a decline of 83% from the average session volume of 623,734 shares. The stock had previously closed at $3.59.

Wall Street Analysts Forecast Growth

Separately, Weiss Ratings restated a “sell (e+)” rating on shares of Briacell Therap in a research note on Friday, July 17th. One analyst has rated the stock with a Sell rating, According to data from MarketBeat.com, the stock has an average rating of “Sell”.

Briacell Therap Stock Down 1.1%

The firm’s 50 day simple moving average is $3.56 and its two-hundred day simple moving average is $3.73. The stock has a market cap of $30.71 million, a P/E ratio of -0.45 and a beta of 1.10.

Briacell Therap (NASDAQ:BCTX) last posted its quarterly earnings results on Tuesday, June 9th. The company reported ($0.99) EPS for the quarter.

Institutional Inflows and Outflows

An institutional investor recently bought a new stake in Briacell Therap stock. Citadel Advisors LLC purchased a new stake in shares of Briacell Therap (NASDAQ:BCTX) in the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund purchased 11,055 shares of the company’s stock, valued at approximately $122,000. Citadel Advisors LLC owned 1.63% of Briacell Therap as of its most recent filing with the Securities and Exchange Commission (SEC). 15.42% of the stock is owned by hedge funds and other institutional investors.

About Briacell Therap

BriaCell Therapeutics Corp., a clinical stage immuno-oncology company, engages in developing targeted immunotherapies to transform cancer care. Its lead candidate is Bria-IMT, a targeted cell-based immunotherapy that is being evaluated in a pivotal Phase 3 combination study for metastatic breast cancer. The company is also developing Bria-OTS, a platform of personalized off-the-shelf cell-based immunotherapies, which is being evaluated in a Phase 1/2 clinical studies targeting breast cancer with extension to prostate cancer and other cancers.